The combined products will provide customers with a comprehensive solution for managing next-generation sequencing workflows in the lab.
The company purchased Tute in a stock-based transaction that closed last month.
The platform features a more comprehensive list of pipelines, simplifies data movement and flow, and reduces analysis times.
HUG's genetic medicine arm will use Saphetor's software and variant knowledgebase in clinical projects focused on developmental and neurological disorders.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The company is currently testing two versions of the software, one for clinical and one for research use, in an early-access program.
The high-quality assembly contains clues to carotenoid pigment accumulation and past evolutionary events in the carrot-containing euasterid II clade.
In Nature this week: high-fidelity CRISPR/Cas9 nuclease, and more.
In Nature this week: cryo-electron microscopy is the Method of the Year, and more.
Researchers at the Manchester Centre for Genomic Medicine are using the platform to identify genetic alterations tied to cancer and developmental disorders and disabilities.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.